# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of tar...
Targeting IDE397 Phase 2 monotherapy expansion dose clinical data update in over ~15 evaluable MTAP lung and bladder cancer p...
Stifel analyst Benjamin Burnett maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and raises the price target from $55 t...
IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of tar...
Goldman Sachs analyst Corinne Jenkins maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and lowers the price target from...
Wedbush analyst Robert Driscoll reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and maintains $52 price target.